Sino Biological has independently developed and established a nanobody platform with a large storage capacity. Through this platform, candidate nanobodies for the drug target PD-L1 were successfully obtained with competitive screening. In our experiments, we demonstrated that this nanobody’s affinity is comparable to that of positive control antibodies, while its blocking and cellular activities were superior to positive controls.
We also produce nanobodies through CROs for our customers. We only need an amino acid sequence to start, and we’ll perform all the steps from gene synthesis to construction, transformation, and purification. We have launched many high-throughput productions for screening purposes. For example, we can produce up to 1000 nanobody constructs per batch within three to four weeks.
“This way, scientists can perform screening on a large list of candidates and only pick ones with good yield, good stability, and good binding characteristics.”
Many of the constructs are bispecific or trispecific. Once the good candidates are selected, we can scale-up production for subsequent characterization experiments. To sum up, we can help researchers develop the best nanobodies for their applications by supplying reagents and offering screening and characterization services.